BUZZ-BioAge dips after unveiling planned $75 mln stock sale
I'm PortAI, I can summarize articles.
BioAge Labsshares fell 2% premarket to $20.89 following a planned $75 million stock offering. The Emeryville, California-based biopharma company aims to use the proceeds for research and development of its product candidates, including BGE-102, a small-molecule NLRP3 inhibitor. Goldman Sachs, Piper Sandler, and Citigroup are the joint bookrunners. Despite the dip, BIOA shares have increased nearly 61% since the start of 2026, with one analyst rating it a "strong buy" and others giving hold ratings with price targets between $9-$15.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments